Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Cullinan Therapeutics Inc’s stock clocked out at $10.59, up 0.09% from its previous closing price of $10.58. In other words, the price has increased by $0.09 from its previous closing price. On the day, 0.78 million shares were traded. CGEM stock price reached its highest trading level at $10.7989 during the session, while it also had its lowest trading level at $10.285.
Ratios:
To gain a deeper understanding of CGEM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.45 and its Current Ratio is at 10.45. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $30.UBS initiated its Buy rating on October 24, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 24 ’25 when Michaelson Jennifer sold 4,000 shares for $12.30 per share. The transaction valued at 49,200 led to the insider holds 138,004 shares of the business.
JENNIFER MICHAELSON bought 4,000 shares of CGEM for $37,880 on Nov 24 ’25. On Oct 28 ’25, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 165,667 shares for $8.40 each. As a result, the insider paid 1,391,686 and bolstered with 8,963,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 625617600 and an Enterprise Value of 294209568.
Stock Price History:
The Beta on a monthly basis for CGEM is -0.09, which has changed by -0.16614175 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, CGEM has reached a high of $13.60, while it has fallen to a 52-week low of $5.68. The 50-Day Moving Average of the stock is 28.55%, while the 200-Day Moving Average is calculated to be 33.14%.
Shares Statistics:
It appears that CGEM traded 1.14M shares on average per day over the past three months and 1746990 shares per day over the past ten days. A total of 59.08M shares are outstanding, with a floating share count of 39.45M. Insiders hold about 33.22% of the company’s shares, while institutions hold 77.35% stake in the company. Shares short for CGEM as of 1763078400 were 6678836 with a Short Ratio of 5.84, compared to 1760486400 on 6629787. Therefore, it implies a Short% of Shares Outstanding of 6678836 and a Short% of Float of 13.08.
Earnings Estimates
Cullinan Therapeutics Inc (CGEM) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.87 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$3.2 and -$4.14 for the fiscal current year, implying an average EPS of -$3.59. EPS for the following year is -$3.35, with 7.0 analysts recommending between -$2.59 and -$3.86.
